SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CMTR-CHEMTRAK FDA OK

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rocketman who wrote (611)4/8/1997 2:29:00 AM
From: Rocketman   of 1172
 
New Controller, not what we need is more revenue.....

Monday April 7 9:14 PM EDT

ChemTrak Inc. names controller

SUNNYVALE, Calif.--(BW HealthWire)--April 7, 1997-- Chemtrak Inc , a leader in the development and marketing of personal diagnostics, Monday
announced the promotion of Peter T. Musso to the position of controller to head the company's accounting department.

Musso has held the position of manager, financial analysis and planning since joining ChemTrak in February 1996. Prior to joining ChemTrak, Musso held
various accounting and financial analysis positions with Syntex Corp. Musso holds a bachelor of science in accounting from California State University,
Hayward.

"We are looking forward to Mr. Musso applying his accounting and financial expertise to the building of our financial team," said Edward F. Covell,
president and chief executive officer.

ChemTrak is a full-service personal diagnostics company that develops and manufactures reliable and easy-to-use medical testing systems. ChemTrak test
kits are designed to screen and diagnose health conditions with accuracy comparable to physicians office and laboratory instrument tests.

Except for the historical information contained herein, this news release contains forward-looking statements that involve risks and uncertainties -- as well
as other risks detailed from time to time in the company's SEC reports, including the report on Form 10K for the year ended Dec. 31, 1996 and Form
10Q for the Quarters ended June 31, 1996 and Sept. 31, 1996. Actual results might differ materially from these statements due to risks and uncertainties,
including determinations by the FDA, the impact of competitive product and pricing, the timely development and acceptance of new products and medical
market conditions.

CONTACT: Freeman/McCue Public Relations
714/557-3663
or
ChemTrak Inc., Sunnyvale
Edward F. Covell, 408/773-8156
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext